Stem cell transplantation for indolent lymphoma.

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Stem cell transplantation (SCT) is a primary treatment for relapsed aggressive non-Hodgkin's lymphoma (NHL).
• The use of SCT for low-grade NHL is debated, but increasing numbers of patients with advanced-stage follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia undergo SCT.
• Autologous SCT using peripheral blood stem cells (PBSC) is common, but concerns about toxicity and long-term risks like myelodysplastic syndrome are rising.

Purpose of the Study:

• To evaluate the evolving role of SCT in NHL management.
• To explore the renewed interest in allogeneic SCT for NHL.
• To investigate the potential of graft-versus-lymphoma effects in allogeneic SCT.

Main Methods:

• Review of current practices in autologous SCT for NHL.
• Analysis of emerging data on allogeneic SCT for NHL.
• Exploration of strategies to enhance graft-versus-lymphoma responses.

Main Results:

• Autologous SCT, primarily with PBSC, is widely used for NHL.
• Concerns regarding autologous SCT toxicity, including myelodysplastic syndrome risk, are increasing.
• Allogeneic SCT is gaining attention due to its potential graft-versus-lymphoma effect.

Conclusions:

• Allogeneic SCT offers a potential advantage over autologous SCT for NHL due to the graft-versus-lymphoma effect.
• Further research is ongoing to optimize donor cell manipulation for enhanced anti-lymphoma activity.
• The role of SCT in NHL treatment continues to evolve, with a shift towards exploring allogeneic options.